6th Digital Pharma & Life Sciences Conference 2011

22 February 2011, Wiesbaden, Germany.
For the sixth time Microsoft and its partners will be holding the Digital Pharma & Life Sciences conference. The lecture event and exhibition is aimed at the pharmaceutical, chemical and life sciences industries, showing current projects and innovative technologies that support greater sustainability, cost efficiency and competitiveness in and through IT.

IT has become a critical competitive factor as an instrument for sustainable climate and environmental protection. The framework is set by international initiatives by industries and governments: for example more than 500 investors request global listed companies to report their CO2 relevant business data through the Carbon Disclosure Project (CDP) from the UK. Global initiatives for Green Chemistry such as the conventions from Stockholm, Rotterdam and Basel, the OECD and the regulatory authorities of developed countries are working to create global standards for sustainable risk and chemicals management.

For this reason, the Digital Pharma & Life Sciences conference 2011 is focussing on the topics "Green IT – Green Chemistry". With the focus on "Green in IT", experts will discuss latest developments of Green IT technologies on the basis of recent successful projects in order to make processes more efficient, save resources and energy and thereby reduce costs. These include concepts for IT virtualization in controlling chemical production or cloud computing for pharmaceutical research.

The "Green through IT" presentations will show pioneering Green Chemistry projects that ensure sustainability in production, research and development and overall global supply chains. Leading companies from the chemical, pharmaceutical and life sciences industries demonstrate how they coordinate production and logistics processes better through intelligent technologies, plan forward-looking and therefore design initiatives for more economically measurable sustainability.

The conference takes place on 22nd February 2011 in the Kurhaus Wiesbaden and is aimed at decision makers and experts from the fields of IT and business management, research and development, business development management, product management, production, quality management, sales and controlling.

During the accompanying exhibition, the partners of the Digital Pharma & Life Sciences initiative will show latest IT technologies and reference projects. On the eve of the conference on 21st February 2011, an exclusive dinner will take place with all the speakers, conference participants and partners of the initiative.

Further information for registration, the agenda and logistic details are available at:
http://www.digitalpharma.de

Most Popular Now

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Time-restricted eating reshapes gene expression th…

Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a ...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...